SGLT2 Inhibition in the Comorbid CKD patient

Published: 22 February 2022

  • Views:

    Views Icon 34548

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

At e-SPACE CRM 2022 clinical data was analysed through a practical lens to address questions around SGLT2 inhibitor use in CKD.

 

Explore the data-supported discussion of the treatment landscape for patients with CKD, and other comorbidities. The inciteful conversation is led by Dr Muthiah Vaduganathan (Chair) and Professor Mustafa Arici.

This symposium was endorsed by University of Groningen and supported by an unrestricted educational grant from AstraZeneca.

This educational symposium will increase delegates' understanding of:

  • SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
  • Data supporting the cardiorenal efficacy of SGLT2 inhibition in comorbid patients with CKD
  • How clinical data from SGLT2 inhibitor trials should be applied in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists

More from this programme

Part 1

Welcome and Introductions

Overview of the symposium agenda followed by a patient case with CKD, mild HFrEF, and no T2D will be presented with a view of exploring how SGLT2 inhibitor therapy could slow CKD progression and manage HF simultaneously.
1 session
Welcome and Introductions Watch now

Part 2

Clinical data through a practical lens

A discussion session featuring supporting data around the use of SGLT2 inhibitor therapy for slowing CKD progression and managing HF in the patient case.
1 session
Clinical data through a practical lens Watch now

Part 3

Discussion and Q&A

A discussion and Q&A with Dr Muthiah Vaduganathan and Prof Mustafa Arici.
1 session
Discussion and Q&A Watch now

Faculty Biographies

Muthiah Vaduganathan

Muthiah Vaduganathan

Co-Director, Center for Cardiometabolic Implementation Science

Prof Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.

View full profile